Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has received European Commission approval as an add-on to standard therapy for adults with acetylcholine receptor (AChR) antibody-positive generalised myasthenia gravis (gMG). The treatment is a dual-binding nanobody C5 inhibitor designed for once-weekly subcutaneous self-administration through an autoinjector.
The approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and is based on results from the Phase 3 PREVAIL trial. The study met its primary endpoint, demonstrating an improvement from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared with placebo. Clinically meaningful improvements were observed as early as the first week of treatment and were sustained through week 26.
The PREVAIL trial was a global, randomised, double-blind, placebo-controlled, multicentre Phase 3 study evaluating the safety and efficacy of Klygefa in adults with gMG. It enrolled 260 patients across 20 countries in North America, Europe, Asia and the Pacific region. Participants had a confirmed diagnosis of gMG for at least three months, tested positive for AChR autoantibodies and were classified as Class II to IV under the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification.
Patients were randomly assigned in a 1:1 ratio to receive Klygefa or placebo during the 26-week controlled treatment period. The treatment regimen included a single weight-based loading dose on Day 1, followed by weight-based maintenance doses beginning on Day 8 and continuing once weekly. The primary endpoint was the change from baseline in the MG-ADL total score at week 26. The scale measures the impact of gMG on patients’ ability to perform daily activities. Secondary endpoints assessed improvements across other disease-related measures.
Patients who completed the controlled treatment period were eligible to enter an ongoing open-label extension study to further evaluate the safety and efficacy of Klygefa.
The treatment was generally well tolerated, with a safety profile consistent with findings from previous trials of the C5 inhibitors eculizumab and ravulizumab in patients with gMG. Data from the PREVAIL trial were presented at the Myasthenia Gravis Foundation of America Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting and published in JAMA Neurology.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy